AstraZeneca’s Alexion adds to rare disease pipepline
Following its acquisition by drug giant AstraZeneca, New Haven-born Alexion Pharmaceuticals is growing its drug pipeline, agreeing to pay up to $500 million for New Jersey-based Caelum...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Following its acquisition by drug giant AstraZeneca, New Haven-born Alexion Pharmaceuticals is growing its drug pipeline, agreeing to pay up to $500 million for New Jersey-based Caelum...
IsoPlexis, a Branford-based life science technology company, went public in early October, with its stock initially trading at $15 a share. The company’s stock is listed...
A five-year-old Yale program that has helped dozens of drug and medical device companies get their ideas off the ground is now looking to help...
UConn Associate Professor of Medicine Anne Delany has received a $2.2 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to...
Biorez reports four new patents relating to Biorez’s proprietary BioBrace™ Implant, which is a biocomposite soft tissue scaffold intended to reinforce soft tissue repair, and act as a...
By Bill Claffey, tax attorney and partner at the accounting firm Fiondella, Milone and LaSaracina LLP (FML) The Connecticut R&D tax credit allows corporations to...
By Carine Boustany, Ph.D., SVP, US Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim At Boehringer Ingelheim, we innovate ground-breaking medicines to...
There’s a better way to do cancer diagnostics, says Precipio DiagnosticsCEO Ilan Danieli. He points a finger at existing methodologies that stress cost saving over accuracy. While...
ReNetX Bio’s NoGo Trap therapeutic has been given “fast track” status by the Food and Drug Administration. The firm’s mission statement is clear and precise:...
As a co-founder of Cybrexa, Per Hellsund rejoined old colleagues Kevin Didden, Cybrexa board chair, and Kevin Rakin, a director. They are seeking to leverage research developed...